Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px
Collaboration › Details

AbbVie–Morgan Stanley: investor conference, 201909 supply service AbbVie presents at Morgan Stanley Global Healthcare Conference

 

Period Period 2019-09-10
Region Region New York, NY
  Country United States (USA)
Organisations Partner, 1st AbbVie Inc. (NYSE: ABBV)
  Group AbbVie (Group)
  Partner, 2nd Morgan Stanley & Co. LLC
  Group Morgan Stanley (Group)
Products Product Morgan Stanley Global Healthcare Conference 2019 New York
  Product 2 pharmaceutical
Person Person Gonzalez, Richard A. (Abbott 201110 EVP Global Pharmaceuticals before COO)
     

AbbVie Inc.. (8/27/19). "Press Release: AbbVie to Present at the Morgan Stanley Healthcare Conference". North Chicago, IL.

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, September 10, 2019. Richard A. Gonzalez, chairman and chief executive officer, will present at 10:10 a.m. Central time.

A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.


About AbbVie

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, LinkedIn or Instagram.


Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2018 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.


Contact(s)

Media
Adelle Infante
847-938-8745
adelle.infante@abbvie.com

or Investors
Liz Shea
847-935-2211
liz.shea@abbvie.com

   
Record changed: 2019-09-01

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for AbbVie (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px




» top